Güncellenmiş Türkiye psoriasis biyolojik ajan kullanım kılavuzu

1. Gottlieb AB, Dann F, Menter A: Psoriasis and the metabolic syndrome. J Drugs Dermatol 2008;7:563-72.
2. Fortune DG, Richards HL, Griffiths CE: Psychologic factors in psoriasis: consequences, mechanisms, and interventions. Dermatol Clin 2005;23:681-94.
3. Delaporte E: Immune-mediated inflammatory diseases and psoriasis. Ann Dermatol Venereol 2008;135:269-74.
4. Gelfand JM, Troxel AB, Lewis JD, Kurd SK, Shin DB, Wang X et al.: The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007;143:1493-9.
5. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM: Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41:401-7.
6. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T: The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001;137:280-4.
7. Fouéré S, Adjadj L, Pawin H: How patients experience psoriasis: results from a European survey. J Eur Acad Dermatol Venereol 2005;19:3:2-6.
8. Derkx B, Taminiau J, Radema S et al.: Tumour-necrosis-factor antibody treatment in Crohn’s disease. L.ancet 1993; 342:173-4.
9. Mease PJ, Goffe BS, Metz J, et al.: Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial. Lancet 2000; 356:385-90.
10. Chaudhari U, Romano P, Mulcahy LD et al.: Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomised trial. Lancet 2001;357:1842-7.
11. Dharamsi JW, Bhosle M, Balkrishnan R, Yentzer BA, Feldman SR: Using 'number needed to treat' to help conceptualize the magnitude of benefit and risk of tumour necrosis factor-alpha inhibitors fopatients with severe psoriasis. Br J Dermatol 2009; 161:605-16.
12. Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler D et al: British Association of Dermatologists: British Association of Dermatologists guidelines for use of biological interventions in psoriasis. Br J Dermatol 2005;153:486-97.
13. Nast A, Kopp I, Augustin M, Banditt KB, Boehncke WH, Follmann M et al.: German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version). Arch Dermatol Res 2007;299:111-38.
14. aMenter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB et al.: Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biolo- gics. J Am Acad Dermatol 2008;58:826-50.
15. The AGREE Collaboration. Appraisal of Guidelines for Research & Evaluation (AGREE) Instrument. www.agreecollaboration.org
16. Öztürkcan S, Ermertcan AT, Eser E, Sahin MT: Cross validation of the Turkish version of dermatology life quality index. Int J Dermatol 2006;45:1300-7.
17. Finlay AY: Current severe psoriasis and the rule of tens. Br J Dermatol 2005;152:861-7.
18. Katugampola RP, Lewis VJ, Finlay AY: The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis. Br J Dermatol 2007;156:945-50.
19. Bansback N, Sizto S, Sun H, Feldman S, Willian MK, Anis A: Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis. Dermatology. 2009; 219:209-18.
20. Pathirana D, Ormerod AD, Saiag P et al.: European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009;2:1-70.
21. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H; CASPAR Study Group: Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-73.
22. Lebwohl M, Bagel J, Gelfand JM, Gladman D, Gordon KB, Hsu S, Kalb RE et al.: From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol 2008;58:94-105.
23. Keser G, Direskeneli H, Akkoç N, inanç M, Özkara ş, Öngen G ve ark.: Doğanavşargil E: II. RAED Uzlaşı Toplantısı Raporu. 2005; http://www.romatoloji.org/?RAED=RaporveKilavuz&SubShf=Taslak3.
24. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM: Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthitis Rheum 2002;46:3151-8.
25. Chakravarty EF, Michaud K, Wolfe F: Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol 2005;32:2130-5.
26. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85.
27. Patel RV, Clark LN, Lebwohl M, Weinberg JM: Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol 2009; 60:1001-17.
28. Carter JD, Ladhani A, Ricca LR, Valeriano J, Vasey FB: A safety as- sessment of tumor necrosis factor antagonists during preg- nancy: a review of the Food and Drug Administration database. J Rheumatol 2009;36:635-41.
29. Paschou S, Voulgari PV, Vrabie IG, Saougou IG, Drosos AA: Fertility and reproduction in male patients with ankylosing spondylitis treated with infliximab. J Rheumatol 2009; 36:351-4.
30. bMenter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG et al.: Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol 2008;58:106-15.
31. Winthrop KL: Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2006;2:602-10.
32. Stebbins WG, Lebwohl MG: Biologics in combination with nonbiologics: efficacy and safety. Dermatol Ther 2004;17:432-40.
33. Scheinfeld N: Adalimumab: a review of side effects. Expert Opin Drug Saf 2005;4:637-41.
34. Smedby KE, Baecklund E, Askling J: Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics. Cancer Epidemiol Biomarkers Prev 2006;15:2069-77.
35. Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F et al.: Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006;54:692-701.
36. Atzeni F, Turiel M, Capsoni F, Doria A, Meroni P, Sarzi-Puttini P: Autoimmunity and anti-TNF-alpha agents. Ann N Y Acad Sci 2005;1051:559-69.
37. Gordon KB, Langley RG, Leonardi C, Toth D, Menter MA, Kang S, et al.: Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006; 55:598-606.
38. Desai SB, Furst DE: Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol 2006; 20:757-90.
39. Conley J, Nanton J, Dhawan S, Pearce DJ, Feldman SR: Novel combination regimens: biologics and acitretin for the treatment of psoriasis-- a case series. J Dermatolog Treat 2006;17:86-9.
40. Smith EC, Riddle C, Menter MA, Lebwohl M: Combining systemic retinoids with biologic agents for moderate to severe psoriasis. Int J Dermatol 2008;47:514-8.
41. Leonardi CL, Powers JL, Matheson RT et al.: Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349:2014-22.
42. Papp KA: The safety of etanercept for the treatment of plaque psoriasis. Ther Clin Risk Manag 2007;3:245-58.
43. Nuñez-Cornejo C, Borrás-Blasco J, Gracia-Perez A, Rosique-Robles JD, Lopez-Camps V, Casterã E et al: Septic shock and community-acquired pneumonia associated with etanercept therapy. Int J Clin Pharmacol Ther 2008;46:193-7.
44. Ly L, Czarnecki D: The rapid onset of multiple squamous cell carcinomas during etanercept treatment for psoriasis. Br J Dermatol 2007;157:1076-8.
45. Fulchiero GJ Jr, Salvaggio H, Drabick JJ, Staveley-O'Carroll K, Billingsley EM, Marks JG et al.: Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies. J Am Acad Dermatol 2007;56:65-7.
46. Bachmeyer C, Thiolière B, Khosrotehrani K, Cattan E: Acute myelogenous leukemia in a patient receiving etanercept for psoriasis. J Am Acad Dermatol 2007;56:169-70.
47. Nair B, Raval G, Mehta P: TNF-alpha inhibitor etanercept and hematologic malignancies: report of a case and review of the literature. Am J Hematol 2007;82:1022-4.
48. De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys EM, De Keyser F: The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications. Lupus 2005;14:931-7.
49. Kuruvilla J, Leitch HA, Vickars LM, Galbraith PF, Li CH, Al-Saab S, Naiman SC: Aplastic anemia following administration of a tumor necrosis factor-alpha inhibitor Eur J Haematol 2003;71:396-8.
50. Gisondi P, Del Giglio M, Cotena C, Girolomoni G: Combining etanercept and acitretin in the therapy of chronic plaque pso- riasis: a 24-week, randomized, controlled, investigator-blinded pilot trial. Br J Dermatol 2008;158:1345-9.
51. Cheifetz A, Mayer L: Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt Sinai J Med 2005;72:250-6.
52. Gottlieb AB, Evans R, Li S, Dooley LT, Guzzo CA, Baker D et al.: Infliximab induction therapy for patients with severe plaque type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004;51:534-42.
53. Lecluse LL, Piskin G, Mekkes JR, Bos JD, de Rie MA: Review and expert opinion on prevention and treatment of infliximab-related infusion reactions. Br J Dermatol 2008;159:527-36.
54. Menter A, Feldman SR, Weinstein GD, Papp K, Evans R, Guzzo C, et al.: A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007;56:31.1-15.
55. Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C et al.: EXPRESS study investigators: Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, mul- ticentre, double-blind trial. Lancet 2005;366:1367-74.
56. Marcil I, Stern RS: Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet 2001;358:1042-5.
57. Paul CF, Ho VC, McGeown C et al.: Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol 2003;120:211-6.
58. Mahé E, Descamps V, Grossin M, Fraitag S, Crickx B: CD30+ T-cell lymphoma in a patient with psoriasis treated with ciclosporin and infliximab. Br J Dermatol 2003;149:170-3.

APA	ALPER F, ATAKAN Z, GÜRER M, Onsun N, ÖZARMAĞAN G (2010). Güncellenmiş Türkiye psoriasis biyolojik ajan kullanım kılavuzu. , 105 - 112.
Chicago	ALPER Fatma Sibel,ATAKAN ZEHRA NİLGÜN,GÜRER Mehmet Ali,Onsun Nahide,ÖZARMAĞAN Güzide Güncellenmiş Türkiye psoriasis biyolojik ajan kullanım kılavuzu. (2010): 105 - 112.
MLA	ALPER Fatma Sibel,ATAKAN ZEHRA NİLGÜN,GÜRER Mehmet Ali,Onsun Nahide,ÖZARMAĞAN Güzide Güncellenmiş Türkiye psoriasis biyolojik ajan kullanım kılavuzu. , 2010, ss.105 - 112.
AMA	ALPER F,ATAKAN Z,GÜRER M,Onsun N,ÖZARMAĞAN G Güncellenmiş Türkiye psoriasis biyolojik ajan kullanım kılavuzu. . 2010; 105 - 112.
Vancouver	ALPER F,ATAKAN Z,GÜRER M,Onsun N,ÖZARMAĞAN G Güncellenmiş Türkiye psoriasis biyolojik ajan kullanım kılavuzu. . 2010; 105 - 112.
IEEE	ALPER F,ATAKAN Z,GÜRER M,Onsun N,ÖZARMAĞAN G "Güncellenmiş Türkiye psoriasis biyolojik ajan kullanım kılavuzu." , ss.105 - 112, 2010.
ISNAD	ALPER, Fatma Sibel vd. "Güncellenmiş Türkiye psoriasis biyolojik ajan kullanım kılavuzu". (2010), 105-112.

APA	ALPER F, ATAKAN Z, GÜRER M, Onsun N, ÖZARMAĞAN G (2010). Güncellenmiş Türkiye psoriasis biyolojik ajan kullanım kılavuzu. Türkderm-Deri Hastalıkları ve Frengi Arşivi, 44(2), 105 - 112.
Chicago	ALPER Fatma Sibel,ATAKAN ZEHRA NİLGÜN,GÜRER Mehmet Ali,Onsun Nahide,ÖZARMAĞAN Güzide Güncellenmiş Türkiye psoriasis biyolojik ajan kullanım kılavuzu. Türkderm-Deri Hastalıkları ve Frengi Arşivi 44, no.2 (2010): 105 - 112.
MLA	ALPER Fatma Sibel,ATAKAN ZEHRA NİLGÜN,GÜRER Mehmet Ali,Onsun Nahide,ÖZARMAĞAN Güzide Güncellenmiş Türkiye psoriasis biyolojik ajan kullanım kılavuzu. Türkderm-Deri Hastalıkları ve Frengi Arşivi, vol.44, no.2, 2010, ss.105 - 112.
AMA	ALPER F,ATAKAN Z,GÜRER M,Onsun N,ÖZARMAĞAN G Güncellenmiş Türkiye psoriasis biyolojik ajan kullanım kılavuzu. Türkderm-Deri Hastalıkları ve Frengi Arşivi. 2010; 44(2): 105 - 112.
Vancouver	ALPER F,ATAKAN Z,GÜRER M,Onsun N,ÖZARMAĞAN G Güncellenmiş Türkiye psoriasis biyolojik ajan kullanım kılavuzu. Türkderm-Deri Hastalıkları ve Frengi Arşivi. 2010; 44(2): 105 - 112.
IEEE	ALPER F,ATAKAN Z,GÜRER M,Onsun N,ÖZARMAĞAN G "Güncellenmiş Türkiye psoriasis biyolojik ajan kullanım kılavuzu." Türkderm-Deri Hastalıkları ve Frengi Arşivi, 44, ss.105 - 112, 2010.
ISNAD	ALPER, Fatma Sibel vd. "Güncellenmiş Türkiye psoriasis biyolojik ajan kullanım kılavuzu". Türkderm-Deri Hastalıkları ve Frengi Arşivi 44/2 (2010), 105-112.